AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03404349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Adolescence Course
Description: There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
Study NCT01686698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 (Original De Simone formulation)
Description: VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
Study NCT01686698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Study NCT05105828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Share wave fibro scan
Description: Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
Study NCT01464801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Tablet Resveratrol 500 mg 3 times daily for 6 months
Study NCT01464801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet Placebo 3 times daily for 6 months
Study NCT03141983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
Study NCT03141983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
Study NCT02134353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Description: Inhaled mannitol 400 mg BD for 26 weeks
Study NCT02134353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Arm B - Control
Description: Placebo Comparator: Arm B - Control BD for 26 weeks
Study NCT00322127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
Study NCT02062996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Study NCT01889121 — intervention group
Intervention type: BEHAVIORAL
Intervention: Structured psychosocial intervention
Description: This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
Study NCT00805077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
Study NCT00805077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tidal volume
Description: tidal volume of 10 ml/kg of ideal body weight without PEEP
Study NCT02107287 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT Technique
Study NCT01629823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Description: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
Study NCT01629823 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Description: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
Study NCT00676572 — intervention group
Intervention type: OTHER
Intervention: Fiberoptic bronchoscopy; blood test
Description: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
Study NCT02608255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT04053985 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAI combine lenvatinib
Description: TAI combine lenvatinib
Study NCT04053985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: lenvatinib only
Study NCT00669552 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: PCI previously electively scheduled.
Study NCT02317770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Spray
Description: 5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
Study NCT02317770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Lidocaine
Description: The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
Study NCT01928797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac output monitor data
Description: The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
Study NCT00259285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 3 cycles
Study NCT00259285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 3 cycles
Study NCT04533243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5ug/h transdermal fentanyl
Description: 2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
Study NCT04533243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral immediate-released morphine
Description: 5mg immediate-released morphine every 4 hours, double dose before sleep.
Study NCT01474421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo once daily orally for 28 days.
Study NCT01880944 — intervention group
Intervention type: OTHER
Intervention: NC-MRI, CE-MRI
Description: non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* > 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)
Study NCT01871766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
Study NCT01489462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Strength Training
Description: The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
Study NCT01489462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Strength Training
Description: The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
Study NCT01489462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
Study NCT00006099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody hu3S193
Description: Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
Study NCT03466229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Androferti
Study NCT03466229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03922295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic tympanoplasty
Description: In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only
Study NCT03582150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Monitoring with Ambulatory Detox
Description: * Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday.
Study NCT03185585 — intervention group
Intervention type: OTHER
Intervention: Mini Nutrition Assessment (MNA® )
Description: MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
Study NCT03185585 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Older Adult Screening Tool (COAST)
Description: Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
Study NCT01172899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic adjustable gastric band
Description: Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Study NCT01172899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined life style interventions
Description: Control group will receive standard therapy consisting of combined lifestyle interventions.
Study NCT01172899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined life style interventions
Description: Control group will receive standard therapy consisting of combined lifestyle interventions.
Study NCT01355471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: applied topically once daily
Study NCT01355471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applied topically once daily
Study NCT03705988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation(CES)
Description: Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
Study NCT03705988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Cranial Electrotherapy Stimulation( sham CES)
Description: Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
Study NCT02345707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg current formulation
Description: Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
Study NCT02345707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg micronized new formulation 500 M
Description: Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
Study NCT02345707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg unmicronized new formulation 500 U
Description: Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
Study NCT02345707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg micronized new formulation 650 M
Description: Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
Study NCT02345707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg unmicronized new formulation 650 U
Description: Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
Study NCT01911936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM716
Study NCT03505918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No referral for rehabilitation
Description: Intervention is that some patients will not be refered for postoperative physiotherapy.
Study NCT04130581 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
Study NCT04130581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
Study NCT03905213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dressing MEPORE
Description: assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
Study NCT03905213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dressing MEPILEX
Description: assignation to three different authorised and on label dressing: absorbent(MEPILEX)
Study NCT03905213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dressing PICCO
Description: assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
Study NCT02703402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
Study NCT02703402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual of exercises
Description: Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
Study NCT02611921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
Study NCT01871766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dosage and route of administration: 15 mg/kg/dose/day IV.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dosage and route of administration: 90 mg/m\^2/dose twice daily.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid Growth Factor
Description: If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.
Study NCT01871766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Sampling
Description: Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dosage and Route of Administration:~Age >1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.